Siren, L.L.C. Bei Gene, Ltd. Transaction History
Siren, L.L.C.
- $2.26 Trillion
- Q4 2024
A detailed history of Siren, L.L.C. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Siren, L.L.C. holds 653,721 shares of BGNE stock, worth $148 Million. This represents 5.33% of its overall portfolio holdings.
Number of Shares
653,721
Previous 563,314
16.05%
Holding current value
$148 Million
Previous $126 Billion
4.52%
% of portfolio
5.33%
Previous 6.32%
Shares
2 transactions
Others Institutions Holding BGNE
# of Institutions
254Shares Held
42.4MCall Options Held
135KPut Options Held
111K-
Baker Bros. Advisors LP New York, NY9.53MShares$2.16 Billion19.52% of portfolio
-
Capital International Investors Los Angeles, CA6.11MShares$1.39 Billion0.22% of portfolio
-
Primecap Management CO Pasadena, CA5.1MShares$1.16 Billion0.74% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E93.8MShares$862 Million26.88% of portfolio
-
Baillie Gifford & CO3.67MShares$832 Million0.54% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...